BFRI News and Press, Biofrontera Inc. From 08/28/23

WOBURN, MA / ACCESSWIRE / August 28, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces positive topline results from its non-randomized, open-label, multicenter Phase 1 study evaluating t...

2023-08-11 10:12:07 ET Biofrontera Inc. (BFRI) Q2 2023 Earnings Conference Call August 11, 2023, 08:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Confe...

2023-08-11 07:07:52 ET Biofrontera press release ( NASDAQ: BFRI ): Q2 GAAP EPS of -$7.23 misses by $2.62 . Revenue of $5.8M (+31.0% Y/Y) misses by $0.38M . Adjusted EBITDA for the second quarter of 2023 was negative $7.9 million compared with negative $7.1 mill...

Conference call begins at 8:30 a.m. Eastern time today WOBURN, MA / ACCESSWIRE / August 11, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and si...

Trial Results Expected in Mid-2024 WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces that patient enrollment is now complete in the Phase 3 clinic...

WOBURN, MA / ACCESSWIRE / August 4, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2023 before the opening of the U.S. fina...

2023-07-13 14:15:50 ET Biofrontera ( NASDAQ: BFRI ) has announced preliminary revenues for Q2 2023 to be in the range of ~$5.7M to $5.9M vs. consensus of $6.78M , an increase of ~26% to 31% Y/Y. As a result, revenues for the first half of 2023 are anticipated...

Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year WOBURN, MA / ACCESSWIRE / July 13, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, today an...

WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet bri...

2023-07-03 09:51:03 ET Biopharmaceutical company Biofrontera ( NASDAQ: BFRI ) said on Monday that it will effect a 1-for-20 reverse stock split from the close of trading at 11:59 PM today. Biofrontera will begin trading on Nasdaq on a split-adjusted basis from Wednesday, July ...